PPARG and metabolic syndrome: This may be attributed to the previously reported ability of OA to suppress CCAAT/enhancer binding proteins-α (C/EBPα) and peroxisome proliferator activated receptor-γ (PPARγ) expression which are known to be pro-lipogenesis in animal models of metabolic syndrome [41].